Pacira BioSciences (PCRX) Debt to Equity: 2010-2025
Historic Debt to Equity for Pacira BioSciences (PCRX) over the last 13 years, with Sep 2025 value amounting to $0.52.
- Pacira BioSciences' Debt to Equity rose 25.87% to $0.52 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.52, marking a year-over-year increase of 25.87%. This contributed to the annual value of $0.75 for FY2024, which is 428.36% up from last year.
- As of Q3 2025, Pacira BioSciences' Debt to Equity stood at $0.52, which was up 30.75% from $0.40 recorded in Q2 2025.
- Over the past 5 years, Pacira BioSciences' Debt to Equity peaked at $0.94 during Q4 2021, and registered a low of $0.12 during Q2 2024.
- For the 3-year period, Pacira BioSciences' Debt to Equity averaged around $0.31, with its median value being $0.19 (2023).
- As far as peak fluctuations go, Pacira BioSciences' Debt to Equity slumped by 71.84% in 2023, and later skyrocketed by 428.36% in 2024.
- Quarterly analysis of 5 years shows Pacira BioSciences' Debt to Equity stood at $0.94 in 2021, then tumbled by 60.87% to $0.37 in 2022, then tumbled by 61.26% to $0.14 in 2023, then skyrocketed by 428.36% to $0.75 in 2024, then increased by 25.87% to $0.52 in 2025.
- Its Debt to Equity was $0.52 in Q3 2025, compared to $0.40 in Q2 2025 and $0.38 in Q1 2025.